Clinical trials: High Risk Cancer
Pancreatic Cancer
Detection of High Expression Levels of EMT-Transcription Factor mRNAs in Patients With Pancreatic Cancer and Their Diagnostic Potential
The present study is aimed at detecting and measuring mRNA levels of genes involved in epithelial to mesenchymal transition (EMT) in biological samples, i.e.
- Trial name
- NCT04323917
- Testing
- Liquid biopsy
- Where
- Italy
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- Istituto Clinico Humanitas
Prostate Cancer
Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer
This is a research study to test an investigational drug (Not FDA approved), Apalutamide given in combination with Leuprolide acetate (FDA approved) in men diagnosed with high-risk prostate cancer who have already selected to…
- Trial name
- NCT02770391
- Testing
- Leuprolide acetate, Apalutamide, Radical prostatectomy
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
The study is being done to find out whether combining two FDA approved drugs along with radiation therapy for the treatment of high risk localized prostate cancer is safe and well tolerated.
- Trial name
- NCT02064582
- Testing
- Enzalutamide, Leuprolide acetate, radiation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Texas Southwestern Medical Center
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
The goal of this clinical research study is to find the highest safe dose of vorinostat that can be given in combination with idarubicin and ara-C for the treatment of AML and high-risk MDS.
- Trial name
- NCT00656617
- Testing
- Idarubicin, Cytarabine, Vorinostat
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- M.D. Anderson Cancer Center
Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
This is a Phase 3, open-label, single arm trial designed to evaluate Cretostimogene patients with NMIBC who have failed prior BCG therapy.
- Trial name
- BOND-003 (NCT04452591)
- Testing
- Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside
- Where
- 86 sites in United States, Australia and 4 more
- Volunteers
- 190 people
- Sponsor
- CG Oncology, Inc.
Recurrent High Grade Gliomas
Protocol to Distinguish Tumor Recurrence From Treatment-Related Necrosis in Patients With High Grade Gliomas
Brain imaging tests are routinely used to detect the presence of a brain tumor or to evaluate the response to treatment. Sometimes the images obtained are not specific and the only way to establish a diagnosis is by obtaining a…
- Trial name
- NCT00942760
- Testing
- 3T MRI
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Bladder Cancer
High Resolution Imaging for Early and Better Detection of Bladder Cancer
The goal of this study is to develop, optimize, and validate a High Resolution Imaging System in the bladder that displays images in real-time, providing automated diagnostic criteria for bladder cancer screening.
- Trial name
- HRME_Bladder (NCT02340650)
- Testing
- Standard High Resolution Microendoscope and/or Line-Scanning Confocal High Resolution Microendoscope
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- The University of Texas Health Science Center, Houston
High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
This phase II trial tests how well pembrolizumab along with standard of care androgen deprivation therapy, with bicalutamide and gonadotropin releasing hormone agonist, and radiotherapy for the treatment of patients with high…
- Conditions
- High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
- Trial name
- NCT06528210
- Testing
- Gonadotropin Releasing Hormone Agonists and Antagonists, Bicalutamide, Biopsy Procedure
- Sponsor
- OHSU Knight Cancer Institute
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer
This partially randomized phase I/II trial studies the side effects and best dose of c-Met inhibitor AMG 337 when given together with oxaliplatin, leucovorin calcium, and fluorouracil and to see how well they work in treating…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Gastrointestinal Cancer
- Trial name
- NCT02344810
- Testing
- c-Met inhibitor AMG 337, oxaliplatin, leucovorin calcium
- Where
- United States
- Sponsor
- Eastern Cooperative Oncology Group
Cervical Cancer
Trial of Postoperative Chemoradiotherapy With or Without Consolidation Chemotherapy for Cervical Cancer Patients
The purpose of this study is to determine the efficacy and safety of consolidation chemotherapy with paclitaxel plus cisplatin (2 cycles per 3 weeks) following radical hysterectomy and adjuvant chemoradiation (2 cycles per 4…
- Trial name
- NCT01755845
- Testing
- paclitaxel, cisplatin, radiotherapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- xie congying
Glioma
Organoids Derived From Induced-Pluripotent Stem Cells (iPS) From Patients With High Grade Astrocytoma
The objective of this study research proposal is to model human gliomagenesis using 3-Dimensional (3D) brain organoids derived from human induced pluripotent stem cells (hiPSCs).
- Trial name
- GLIOMANOID (NCT03971812)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Cancer of Rectum
Standard Dose Versus High Dose of Radiotherapy in Rectal Preservation With Chemo-radiotherapy in Rectal Cancer Patients
In recent years, an increasing number of retrospective and prospective observational studies have indicated that a subset of rectal cancer patients may avoid surgery if they can achieve a complete response to chemoradiotherapy.
- Trial name
- WW3 (NCT04095299)
- Testing
- 50.4 Gy to the tumor and elective volume, 62 Gy to the clinical tumor volume and 50.4 Gy to the elective volume, Capecitabine 825 mg/m2 twice daily on weekdays
- Where
- 5 sites in Denmark
- Volunteers
- 162 people
- Sponsor
- Vejle Hospital
Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx).
- Conditions
- Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer
- Trial name
- POTENTIATE (NCT05827614)
- Testing
- BBI-355, Erlotinib, Futibatinib
- Where
- 16 sites in United States
- Volunteers
- 85 people
- Sponsor
- Boundless Bio, Inc.
Metastatic Carcinoma in the Liver, Stage IV Colorectal Cancer
High Definition Single Cell Analysis in Colorectal Cancer
This research clinical trial studies high definition single cell analysis in blood and tissue samples from patients with colorectal cancer which has spread to the liver.
- Trial name
- NCT02809716
- Testing
- Biomarker Analysis, Cytology Specimen Collection Procedure
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Southern California
Sarcoma,Soft Tissue
Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)
Soft tissue sarcomas (STSs) are rare cancers with a 5-year survival rate of 60%, and there is no standard treatment for high-risk extremity and trunk STSs (eSTS).
- Trial name
- TNT-HYPE (NCT06835049)
- Testing
- Doxorubicin, Ifosfamide, Dacarbazine
- Where
- 8 sites in Switzerland
- Volunteers
- 24 people
- Sponsor
- Swiss Cancer Institute
Esophageal Carcinoma
Comparable Study of Different Radiation Dose in Esophageal Carcinoma
Radiation therapy plus concurrent chemotherapy is now the standard therapy for patients with localized carcinoma of the esophagus selected for nonsurgical treatment.
- Trial name
- NCT01937208
- Testing
- intensity modulated radiation therapy in both arms, concurrent chemotherapy with radiation
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Zhejiang Cancer Hospital
Multiple Myeloma
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
This is a randomized, 2-arm phase II, placebo-controlled, multi-center study, where the investigators aim to evaluate whether the reported benefits of denosumab, delay of SRE and decrease in myeloma growth promotion, reduce the…
- Trial name
- DEFENCE (NCT03792763)
- Testing
- Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
- Where
- 10 sites in Austria, Germany and 1 more
- Volunteers
- 8 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Rectal Cancer
Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal Cancer
This is a prospective, multicenter, open-label, single-arm Phase II study designed to evaluate the efficacy and safety of total neoadjuvant mFOLFOX6 combined with suvemcitug and enlonstobart in patients with MRI（Magnetic…
- Trial name
- SPARE (NCT07810114)
- Testing
- mFOLFOX6, Suvemcitug, Enlonstobart
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Fudan University
Neuroblastoma
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
The purpose of this study is to find out what effects, good and/or bad, the combination of 3F8 and GM-CSF has on the patient and the cancer.
- Trial name
- NCT01183884
- Testing
- 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia
Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- LAL0904 (NCT00458848)
- Testing
- asparaginase, daunorubicin hydrochloride, etoposide
- Where
- 66 sites in Italy
- Volunteers
- 470 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.